

## Farmakologická léčba

- 2 **Moderní protinádorová léčba – individualizovaná terapie, bioindikátory efektu a toxicita terapie, nová léčiva**  
MUDr. Denisa Vitásková | prof. MUDr. Bohuslav Melichar, Ph.D. Onkologická klinika, LF Univerzity Palackého a FN Olomouc
- 2 **Systémová léčba zhoubných nádorů ledvin a novinky v roce 2014**  
doc. MUDr. Milada Zemanová, Ph.D. Onkologická klinika 1. LF UK a VFN, Praha
- 2 **Kolorektální karcinom: strategie pro včasnou diagnostiku**  
doc. MUDr. Bohumil Seifert, Ph.D. Ústav všeobecného lékařství 1. lékařské fakulty UK v Praze
- 3 **Individualizace adjuvantní/neoadjuvantní terapie nádorů prsu**  
MUDr. Adam Paulík | prof. MUDr. Stanislav Filip, Ph.D., DrSc. Klinika onkologie a radioterapie FN Hradec Králové
- 3 **Nintedanib, trojitý inhibitor angiokináz**  
MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN Motol
- 3 **Pleurální výpotek u pacientů s chronickou myeloidní leukémií léčených dasatinibem**  
MUDr. Hana Klamová, CSc. Ústav hematologie a krevní transfuze Praha
- 4 **Troponiny jako bioindikátory určitých typů kardiotoxicity léčiv**  
doc. MUDr. Michaela Adamcová, Ph.D. Ústav fyziologie, LF v Hradci Králové, Univerzita Karlova v Praze
- 4 **Glukokortikoidy šetřící léčba u systémového lupus erythematoses – zaměřeno na belimumab**  
MUDr. Hana Ciferská, Ph.D. Revmatologický ústav a Revmatologická klinika 1. LF UK a VFN, Praha  
MUDr. Jan Vachek Klinika nefrologie VFN a 1. LF UK, Praha
- 5 **Mirabegron: nové možnosti terapie hyperaktivního močového měchýře**  
MUDr. Roman Staněk Urologické oddělení Slezské nemocnice Opava
- 5 **Metoprolol**  
prof. MUDr. Jan Bultas, CSc. Farmakologický ústav 3. LF UK Praha
- 6 **AMESOS – fixní kombinace lisinoprilu a amlodipinu v léčbě hypertenze**  
MUDr. Jiří Slíva, MD., Ph.D. Ústavy farmakologie 2. a 3. LF UK Praha
- 6 **Farmakologická léčba obezity a diabetu**  
prof. MUDr. Martin Haluzík, DrSc. III. interní klinika 1. LF UK a VFN, Praha
- 7 **Praktické využití fixní kombinace perindopril/indapamid u nemocného s metabolickým syndromem**  
doc. MUDr. Jitka Seidlerová, Ph.D. Lékařská fakulta v Plzni, Univerzita Karlova v Praze, Biomedicínské centrum, Lékařská fakulta v Plzni, Univerzita Karlova v Praze, Plzeň
- 7 **Personalizovaná léčba deprese**  
prof. MUDr. Jiří Raboch, DrSc. Psychiatrická klinika 1. LF UK a VFN
- 7 **Individualizace farmakologické léčby v psychiatrii – zaostřeno na schizofrenii**  
prof. MUDr. Eva Češková, CSc. CEITEC – MU, Psychiatrická klinika FN Brno, Katedra interních oborů LF Ostravské univerzity v Ostravě, Oddělení psychiatrické FN Ostrava  
prof. MUDr. Ladislav Hosák, Ph.D. Psychiatrická klinika LF UK a FN Hradec Králové
- 8 **Dlouhodobá účinnost glatiramer acetátu v podmínkách klinické praxe**  
MUDr. Jiří Slíva, MD., Ph.D. Ústavy farmakologie 2. a 3. LF UK Praha
- 8 **Nové trendy ve vakcinologii**  
MUDr. Veronika Horáková Ústav imunologie 2. LF a FN v Motole, Praha
- 8 **Avanafil – nová možnost volby v léčbě erektilní dysfunkce**  
MUDr. Lukáš Bittner, FEBU, FECSM Urologická klinika 3. LF UK a FNKV

# Moderní protinádorová léčba – individualizovaná terapie, bioindikátory efektu a toxicita terapie, nová léčiva

MUDr. Denisa Vitásková | prof. MUDr. Bohuslav Melichar, Ph.D.

Onkologická klinika, LF Univerzity Palackého a FN Olomouc

- 1 Adam, Z. – Vorlíček, J. – Vaníček, J., et al.: *Diagnostické a léčebné postupy u maligních chorob*. II. aktualizované a doplněné vydání. Grada, Praha, 2004.
- 2 Adams, J. – Palombella, V. J. – Sausville, E. A., et al.: Proteasome inhibitors: a novel class of potent and effective antitumor agents. *Cancer Res*, 1999, 59, s. 2615–2622.
- 3 Baselga, R.: Anti-EGFR therapy: A new targeted approach to cancer treatment. *Oncology Biotherapeutics*, 2002, 2, s. 1–36.
- 4 Bianco, R. – Daniele, G. – Ciardiello, F.: Monoclonal antibodies targeting the epidermal growth factor receptor. *Curr Drug Targets*, 2005, 6, s. 275–287.
- 5 Dunn, G. P. – Old, L. J. – Schreiber, R. D.: The immunobiology of cancer immunosurveillance and immunoeediting. *Immunity*, 2004, 21, s. 137–148.
- 6 Klener, P. – Klener, P. jr.: *Nová protinádorová léčiva a léčebné strategie v onkologii*. Grada, Praha, 2009.
- 7 Pardanani, A. – Tefferi, A.: Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. *Blood*, 2004, 104, s. 1931–1939.
- 8 Stern, M. – Hermann, R.: Overview of monoclonal antibodies in cancer therapy: present and promise. *Crit Rev Oncol Hematol*, 2005, 54, s. 11–29.
- 9 Stewart, T. J. – Abrams, S. I.: How tumors escape mass destruction. *Oncogene*, 2008, 27, s. 5894–5903.
- 10 Tibes, R. – Trent, J. – Kurzrock, R.: Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. *Annu Rev Pharmacol Toxicol*, 2005, 45, s. 357–384.
- 11 Vanneman, M. – Dranoff, G.: Combining immunotherapy and targeted therapies in cancer treatment. *Nat Rev Cancer*, 2012, 12, s. 237–251.

## Systémová léčba zhoubných nádorů ledvin a novinky v roce 2014

doc. MUDr. Milada Zemanová, Ph.D. Onkologická klinika 1. LF UK a VFN, Praha

- 1 Novotvary 2007 ČR. ÚZIS ČR, 2010, www.svod.cz.
- 2 Hes, O. – Hora, M. – Michal, M.: Nová klasifikace nádorů ledvin dle WHO 2004 – komentovaný přehled. *Urol Listy*, 2004, 3, s. 40–44.
- 3 Motzer, R. J. – Bacik, J. – Mazumdar, M.: Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience. *Clin Cancer Res*, 2004, 10, s. 6302–6303.
- 4 Negrier, S., et al.: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. *N Engl J Med*, 1998, 338, s. 1273–1278.
- 5 Negrier, S. – Perol, D. – Ravaud, A., et al.: Medroxyprogesterone, interferon alfa-2a, interleukin 2 or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis. *Cancer*, 2007, 110, s. 2448–2457.
- 6 Kaelin, W. G.: Molecular basis of the VHL hereditary cancer syndrome. *Nat Rev Cancer*, 2002, 2, s. 673–682.
- 7 Melichar, B. – Procházková-Študentová, H. – Vitásková, D., et al.: Bevacizumab in combination with IFN- $\alpha$  in metastatic renal cell carcinoma: the AVOREN trial. *Expert Rev Anticancer Ther*, 2012, 12, s. 1253–1261.
- 8 Escudier, B., et al., for the TARGET Study Group: Sorafenib in advanced clear-cell renal-cell carcinoma. *N Engl J Med*, 2007, 356, s. 125–134.
- 9 Motzer, R. J. – Hutson, T. E. – Tomczak, P., et al.: Overall survival and updated results for sunitinib compared with interferon (IFN)- $\alpha$  in patients with metastatic renal cell carcinoma (mRCC). *J Clin Oncol*, 2009, 27, s. 3584–3590.
- 10 Sternberg, C. N. – Davis, I. D. – Kardiak, J., et al.: Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. *J Clin Oncol*, 2010, 28, s. 1061–1068.
- 11 Motzer, R. J. – Hutson, T. E. – Cella, D., et al.: Pazopanib versus sunitinib in metastatic renal-cell carcinoma. *N Engl J Med*, 2013, 369, s. 722–731, doi: 10.1056/NEJMoa1303989.
- 12 Escudier, B. – Porta, C. – Bono, P., et al.: Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. *J Clin Oncol*, 2014, 32, s. 1412–1418, doi: 10.1200/JCO.2013.50.8267, Epub 31. 3. 2014.
- 13 Rini, B. I. – Escudier, B. – Tomczak, P., et al.: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial. *Lancet*, 2011, 378, s. 1931–1939.
- 14 Hudes, G., et al., for the Global ARCC Trial: Temsirolimus, interferon- $\alpha$ , or both for advanced renal-cell carcinoma. *N Engl J Med*, 2007, 356, s. 2271–2281.
- 15 Motzer, R. – Escudier, B. – Oudard, S., et al.: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. *Lancet*, 2008, 372, s. 449–456.
- 16 Büchler, T. – Klapka, R. – Melichar, B., et al.: Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma—data from the Czech registry. *Ann Oncol*, 2012, 23, s. 395–401, Epub 2. 5. 2011.
- 17 Iacovelli, R. – Carteni, G. – Sternberg, C. N., et al.: Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort. *Eur J Cancer*, 2013, 49, s. 2134–2142, doi: 10.1016/j.ejca.2013.02.032, Epub 18. 5. 2013.
- 18 Motzer, R. J. – Porta, C. – Vogelzang, N. J., et al.: Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. *Lancet Oncol*, 2014, 15, s. 286–296, doi: 10.1016/S1470-2045(14)70030-0, Epub 17. 2. 2014.
- 19 Bhojani, N. – Jeldres, C. – Petard, J. J., et al.: Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. *Eur Urol*, 2008, 53, s. 917–930.
- 20 Morse, M. – McDermott, D. F. – Daniels, G. A., et al.: High-dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR). *J Clin Oncol*, 32, 5s, 2014 (dopl.; abstrakt 4523).
- 21 Motzer, R. J. – Rini, B. I. – McDermott, D. F., et al.: Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial. *J Clin Oncol*, 2014, 32, 5s (dopl.; abstrakt 5009).
- 22 Choueiri, T. K. – Fishman, M. N. – Escudier, B. J., et al.: Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial. *J Clin Oncol*, 2014, 32, 5s (dopl.; abstrakt 5012).
- 23 Hammers, H. J. – Plimack, E. R. – Infante, J. R., et al.: Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). *J Clin Oncol*, 2014, 32, 5s (dopl.; abstrakt 4504).
- 24 Amin, A. – Plimack, E. R. – Infante, J. R., et al.: Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). *J Clin Oncol*, 2014, 32, 5s (dopl.; abstrakt 5010).
- 25 Amin, A. – Dudek, A. Z. – Logan, T. F., et al.: Long-term survival in unfavorable-risk mRCC patients treated with a combination of autologous immunotherapy (AGS-003) plus sunitinib. *J Clin Oncol*, 2014, 32, 5s (dopl.; abstrakt 4524).
- 26 Escudier, B. J. – Koscielny, S. – Lopatin, M., et al.: Validation of a 16-gene signature for prediction of recurrence after nephrectomy in stage I–III clear cell renal cell carcinoma (ccRCC). *J Clin Oncol*, 2014, 32, 5s (dopl.; abstrakt 4502).
- 27 Johnson, T. – Xu, Ch. – Choueiri, T. K., et al.: Genome-wide association study (GWAS) of efficacy and safety endpoints in pazopanib- or sunitinib-treated patients with renal cell carcinoma (RCC). *J Clin Oncol*, 2014, 32, 5s (dopl.; abstrakt 4503).
- 28 Rini, B. I. – Dorff, T. B. – Elson, P., et al.: A prospective observational study of metastatic renal cell carcinoma (mRCC) prior to initiation of systemic therapy. *J Clin Oncol*, 2014, 32, 5s (dopl.; abstrakt 4520).
- 29 Mittal, K. – Derosa, L. – Albiges, L., et al.: Outcomes of treatment cessation in select metastatic renal cell carcinoma (mRCC) patients. *J Clin Oncol*, 2014, 32, 5s (dopl.; abstrakt 4521).
- 30 Alvarez, A. L. – Plimack, E. R. – Dreicer, R., et al.: A phase II study of pazopanib (P) in patients (Pts) with localized renal cell carcinoma (RCC) to enable partial nephrectomy (PN). *J Clin Oncol*, 2014, 32, 5s (dopl.; abstrakt 4522).

## Kolorektální karcinom: strategie pro včasnou diagnostiku

doc. MUDr. Bohumil Seifert, Ph.D. Ústav všeobecného lékařství 1. lékařské fakulty UK v Praze

- 1 Vybrané internetové odkazy: www.svod.cz, www.kolorektum.cz.
- 2 *Věstník Ministerstva zdravotnictví ČR*, ročník 2009, částka 1, vydán v únoru 2009.
- 3 Segnan, N. – Patnick, J. – Von Karsa, L.: European guidelines for quality assurance in colorectal cancer screening and diagnosis – First edition. European Commission, Luxembourg, Publications Office of the European Union, 2010, doi:10.2772/15379 (elektronická verze).
- 4 Jellema, P., et al.: Value of symptoms and additional diagnostic tests for colorectal cancer in primary care: systematic review and meta-analysis. *BMJ*, 2010, 340, c1269.
- 5 Parente, F., et al.: A combination of faecal tests for the detection of colon cancer: a new strategy for an appropriate selection of referral to colonoscopy? A prospective multicenter italian study. *European Journal of Gastroenterology & Hepatology*, 2012, 24, 10, s. 1145–1152, doi: 10.1097/MEG.0b013e328355cc79.
- 6 Seifert, B.: *Screening kolorektálního karcinomu. Příručka pro všeobecné praktické lékaře*. Maxdorf, 2012.

# Individualizace adjuvantní/neoadjuvantní terapie nádorů prsu

MUDr. Adam Paulík | prof. MUDr. Stanislav Filip, Ph.D., DrSc.

Klinika onkologie a radioterapie FN Hradec Králové

- 1 *Modrá kniha české onkologické společnosti*, 19. aktualizace, s. 263–264.
- 2 **Eiermann, W. – Paepke, S – Appfelstaedt, J., et al.**: Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. *Ann Oncol*, 2001, 12, s. 1527–1532.
- 3 **Semiglazov, V. – Kletsel, A. – Semiglazov, V., et al.**: Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2, T3N0-1, T4N0M0). *J Clin Oncol*, 2005, 23, 16S, abstrakt 530.
- 4 **Ellis, M. E. – Suman, V. J. – Hoog, J., et al.**: Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype—ACOSOG Z1031. *J Clin Oncol*, 2011, 29, s. 2342–2349.
- 5 **Nielsen, T. O. – Paker, J. S. – Leung, S., et al.**: A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. *Cancer Res*, 2010, 16, s. 5222–5232.
- 6 **Sgroi, D. C. – Carney, E. – Zarrella, E., et al.**: Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. *J Natl Cancer Inst*, 2013, 105, s. 1036–1042.
- 7 **Martin, M. – Brase, J. C. – Calvo, L., et al.**: Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2– breast cancer patients: results from the GECAM 9906 trial. *Breast Cancer Res*, 2014, 16 (2), R38, doi: 10.1186/bcr3642.
- 8 **Gianni, L. – Eiermann, W. – Semiglazov, V. S., et al.**: Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT+H) followed by adjuvant H versus CT alone, in patients with HER2 positive locally advanced breast cancer. Prezentováno na: 2013 ASCO Annual Meeting, Oral abstract session. *J Clin Oncol*, 2013, dopl., abstrakt 503.
- 9 **Goldhirsch, A. – Gelber, R. D. – Piccart-Gebhart, M. J., et al.**: 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. *Lancet*, 2013, 382 (9897), s. 1021–1028.
- 10 **Gianni, L. – Pienkowski, T. – Im, Y. H., et al.**: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. *Lancet Oncol*, 2012, 13, s. 25–32.
- 11 **De Azambuja, E. – Holmes, A. P. – Piccart-Gebhart, M., et al.**: Lapatinib with trastuzumab for HER2-positive early breast cancer (Neo-ALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. *Lancet Oncol*, 2014, 15, s. 1137–1146.
- 12 **Piccart-Gebhart, M. – Holme, A. P. – Baselga, J., et al.**: First results from the phase III ALTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). *J Clin Oncol*, 2014, 32, 5, dopl., abstrakt LBA4.
- 13 **Sikov, W. M. – Berry, D. A. – Perou, C. M., et al.**: Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB40603 (Alliance). Prezentováno na: San Antonio Breast Cancer Symposium San Antonio, TX, 2013, abstrakt S5-01.
- 14 **Cameron, D. – Brown, J. – Dent R., et al.**: Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. *Lancet Oncol*, 2013, 14, s. 933–942.
- 15 **Von Minckwitz, G. – Schneeweiss, A. – Salat, C., et al.**: A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). *J Clin Oncol*, 2013, 31, 15, dopl., abstrakt 1004.
- 16 **Untch, M. – Rezaei, M. – Loibl, S., et al.**: Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. *J Clin Oncol*, 2010, 28 (12), s. 2024–2031.

## Nintedanib, trojitý inhibitor angiokináz

MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN Motol

- 1 **Reck, M. – Kaiser, R. – Mellemegaard, A. – Douillard, J. Y., et al.**: Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. *Lancet Oncol*, 2014, 15, s. 143–155, doi: 10.1016/S1470-2045(13)70586-2, Epub 9. 1. 2014.
- 2 **Hanna, N. H.**: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (Lume-lung 2) after failure of first-line chemotherapy. *2013 ASCO Annual Meeting*, abstrakt 8034.

## Pleurální výpotek u pacientů s chronickou myeloidní leukemií léčených dasatinibem

MUDr. Hana Klamová, CSc. Ústav hematologie a krevní transfuze Praha

- 1 **O'Hare, T. – Walters, D. K. – Stoffregen, E. P., et al.**: In vitro activity of Bcr-Abl inhibitors BMS-354825 and AMN107 against clinically relevant imatinib-resistant Abl kinase domain mutants. *Cancer Res* 2005;65:4500–4506.
- 2 **Hochhaus, A. – Baccarani, M. – Deininger, M., et al.**: Dasatinib induces durable cytogenetic response in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. *Leukemia* 2008;22:1200–1206.
- 3 **Mauro, M. J. – Deininger, M. V.**: Management of drug toxicities in chronic myeloid leukaemia. *Best Pract Res Clin Haematol* 2009;22:409–429.
- 4 **Jabbour, E. – Deininger, M. – Hochhaus, A.**: Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. *Leukemia* 2011;25(2):201–210.
- 5 **de Lavallade, H. – Punjalingam, S. – Milojkovic, D.**: Pleural effusion in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. *Br J Haematol* 2008;141:745–471.
- 6 **Kim, D. H. – Kamel-Reid, S. – Chány, H., et al.**: Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. *Haematologica* 2009;94:134–139.
- 7 **Mustjoki, S. – Ekblom, M. – Arstila, T. P., et al.**: Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. *Leukemia* 2009;23:1398–1405.
- 8 **Apperley, J. – Cortes, J.E. – Kim, D. W., et al.**: Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START-A trial. *J Clin Oncol* 2009; 27:3472–279.
- 9 **Shah, N. P. – Kim, D. W. – Kantarjian, H. M., et al.**: Dasatinib dose-optimization in chronic phase myeloid leukemia: two-year data CA180-034 show equivalent long term efficacy and improved safety with 100 mg once daily dose. *Blood* 2008;112:3225.
- 10 **Zackova, D. – Klamova, H. – Muzik, J., et al.**: Efficacy and tolerance of dasatinib after imatinib failure or intolerance for chronic myeloid leukemia patients treated in three different hospitals compare well with results achievable in formal clinical trials. *Leuk Lymphoma* 2013;54(10):2310–2313.
- 11 **Klamova, H. – Faber, E. – Zackova, D., et al.**: Dasatinib in imatinib-resistant or intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic. *Neoplasma* 2010;57:355–359.
- 12 **Latagliata, R. – Breccia, M. – Carmen, F., et al.**: Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukemia. *Hematol Oncol* 2013;31:103–109.
- 13 **Quantas-Cardama, A. – Kantarjian, H. – O'Brien, S., et al.**: Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. *J Clin Oncol* 2007;25:3908–3914.
- 14 **La Rosee, P. – Martiat, P. – Klag, T., et al.**: Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib. *Ann Hematol* 2013;92:1345–1350.

# Troponiny jako bioindikátory určitých typů kardiotoxicity léčiv

doc. MUDr. Michaela Adamcová, Ph.D.

Ústav fyziologie, LF v Hradci Králové, Univerzita Karlova v Praze

- Adamcová, M. – Geršl, V. – Hrdina, R. – Mělka, M. – Mazurová, Y. – Vávrová, J. – Palička, V. – Kokštejn, Z.: Cardiac troponin T as a marker of myocardial damage caused by antineoplastic drugs in rabbits. *J Cancer Res Clin Oncol*, 1999, 125 (5), s. 268–274.
- Adamcová, M. – Šterba, M. – Šimunek, T. – Potacova, A. – Popelova, O. – Mazurova, Y. – Geršl, V.: Troponin as a marker of myocardial damage in drug-induced cardiotoxicity. *Expert Opin Drug Saf*, 2005, 4, s. 457–472.
- Adamcová, M. – Šimunek, T. – Kaiserová, H. – Popelová, O. – Šterba, M. – Potáčková, A. – Vávrová, J. – Maláková, J. – Geršl, V.: In vitro and in vivo examination of cardiac troponins as biochemical markers of drug-induced cardiotoxicity. *Toxicology*, 2007, 237 (1–3), s. 218–228.
- Adamcová, M. – Popelová-Lenčová, O. – Jirkovský, E. – Mazurová, Y. – Geršl, V. – Šterba, M.: Regulatory proteins of myocardium for evaluation of cardiotoxicity. *Acta Physiologica*, 2014, 211, s. 72.
- Berridge, B. R. – Pettit, S. – Walker, D. B. – Jaffe, A. S. – Schultze, A. E. – Herman, E. – Reagan, W. J. – Lipshultz, S. E. – Apple, F. S. – York, M. J.: A translational approach to detecting drug-induced cardiac injury with cardiac troponins: consensus and recommendations from the Cardiac Troponins Biomarker Working Group of the Health and Environmental Sciences Institute. *Am Heart J*, 2009, 158 (1), s. 21–29.
- Bertinchant, J. P. – Robert, E. – Polge, A. – Marty-Double, C. – Fabbro-Peray, P. – Poirey, S. – Aya, G. – Juan, J. M. – Ledermann, B. – de la Coussaye, J. E. – Dauzat, M.: Comparison of the diagnostic value of cardiac troponin I and T determinations for detecting early myocardial damage and the relationship with histological findings after isoprenaline-induced cardiac injury in rats. *Clin Chim Acta*, 2000, 298 (1–2), s. 13–28.
- Bluel, H. – Deschl, U. – Bertsch, T. – Bötz, G. – Rebel, W.: Diagnostic efficiency of troponin T measurements in rats with experimental myocardial cell damage. *Exp Toxicol Pathol*, 1995, 47 (2–3), s. 121–127.
- Brady, S. – York, M. – Scudamore, C. – Williams, T. – Griffiths, W. – Turton, J.: Cardiac troponin I in isoproterenol-induced cardiac injury in the Hanover Wistar rat: studies on low dose levels and routes of administration. *Toxicol Pathol*, 2010, 38, s. 287–291.
- Cardinale, D. – Colombo, A. – Torrisi, R., et al.: Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin evaluation. *J Clin Oncol*, 2010, 28 (25), s. 3910–3916.
- Cardinale, D. – Salvatici, M. – Sandri, M. T.: Role of biomarkers in cardiology. *Clin Chem Lab Med*, 2011, 49 (12), s. 1937–1948.
- Clements, P. – Brady, S. – York, M. – Berridge, B. – Mikaelian, I. – Nicklaus, R. – Gandhi, M. – Roman, L. – Stamp, C. – Davies, D. – McGill, P. – Williams, T. – Pettit, S. – Walker, D.: ILSI HESI Cardiac Troponins Working Group, Turton J. Time course characterization of serum cardiac troponins, heart fatty acid-binding protein, and morphologic findings with isoproterenol-induced myocardial injury in the rat. *Toxicol Pathol*, 2010, 38 (5), s. 703–714.
- Cove-Smith, L. – Woodhouse, N. – Hargreaves, A. – Kirk, J. – Smith, S. – Price, S. A. – Galvin, M., et al.: An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicity. *Toxicol Sci*, 2014, 140 (1), s. 3–15.
- Engle, S. K. – Jordan, W. H. – Pritt, M. L. – Chiang, A. Y., et al.: Qualification of cardiac troponin I concentration in mouse serum using isoproterenol and implementation in pharmacology studies to accelerate drug development. *Toxicol Pathol*, 2009, 37, s. 617–628.
- Hamm, C. W. – Ravkilde, J. – Gerhardt, W. L.: The prognostic value of serum troponin T in unstable angina. *N Engl J Med*, 1992, 327, s. 146–150.
- Hausner, E. A. – Hicks, K. A. – Leighton, J. K. – Szarfman, A. – Thompson, A. M. – Harlow, P.: Qualification of cardiac troponins for nonclinical use: A regulatory perspective. *Regulatory Toxicology and Pharmacology*, 2013, 67, s. 108–114.
- Herman, E. H. – Lipshultz, S. E. – Rifai, N. – Zhang, J. – Papoian, T. – Yu, Z. X. – Takeda, K. – Ferrans, V. J.: Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity. *Cancer Research*, 1998, 58, s. 195–197.
- Herman, E. H. – Zhang, J. – Lipshultz, S. E., et al.: Correlation between serum levels of cardiac troponin T and severity of the chronic cardiomyopathy induced by doxorubicin. *J Clin Oncol*, 1999, 17, s. 2237–2243.
- Herman, E. H. – Ferrans, V. J.: The use of cardiac biomarkers for the detection of drug-induced myocardial damage. In: Adams, J. E. III – Apple, F. S. – Jaffe, A. S. – Wu, A. H. B. (eds.) – Armonk, N. Y.: *Markers in Cardiology: Current and future clinical applications*. Futura Publishing Company, Inc., 2001, s. 211–234.
- Herman, E. H. – Lipshultz, S. E. – Ferrans, V. J.: The use of cardiac markers to detect myocardial damage induced by chemotherapeutic agents. In: Wu, A. H. B. (ed.): *Cardiac Markers*. Humana Press Inc., Totowa, NJ, 2003, s. 87–109.
- www.ifcc.org/media/102202/IFCC\_Troponin\_Table\_vDec\_2010\_FINAL\_ug\_L\_28Jan11.pdf 21, http://www.uniprot.org.
- Jabor, A.: *Natriuretické peptidy*. Roche, Praha, 2010.
- Jirkovský, E. – Lenčová-Popelová, O. – Hroch, M. – Adamcová, M., et al.: Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits. *Toxicology*, 2013, 311, s. 191–204.
- Katus, H. A. – Remppis, A. – Looser, S. – Hallermeier, K. – Scheffold, T. – Kübler, W.: Enzyme-linked immunoassay of cardiac troponin T for detection of acute myocardial infarction in patients. *J Mol Cell Cardiol*, 1989, 21, s. 1349–1353.
- Katus, H. A. – Remppis, A. – Scheffold, T. – Diederich, K. W. – Kuebler, W.: Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction. *Am J Cardiol*, 1991, 67, s. 1360–1367.
- Koh, E. – Nakamura, T. – Takahashi, H.: Troponin T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats. *Circ J*, 2004, 68 (2), s. 163–167.
- Kurata, M. – Iidaka, T. – Sasayama, Y. – Fukushima, T. – Sakimura, M. – Shirai, N.: Correlation among clinicopathological parameters of myocardial damage in rats treated with isoproterenol. *Exp Anim*, 2007, 56 (1), s. 57–62.
- Lang, K. – Sigusch, H. H. – Börner, A. – Hoffmann, M., et al.: Minimal myocardial lesions caused by endomyocardial biopsy can be detected by a commercially available cardiac troponin T enzyme-linked immunosorbent assay. *Eur J Clin Invest*, 1996, 26, s. 451–453.
- Mair, J. – Artnert-Dworzak, E. – Leichter, P., et al.: Cardiac troponin T diagnosis of acute myocardial infarction. *Clin Chem*, 1991, 37, s. 845–852.
- Mladenka, P. – Hrdina, R. – Bobrovová, Z. – Semecky, V. – Vávrová, J. – Holečková, M. – Palicka, V. – Mazurová, Y. – Nachtigal, P.: Cardiac biomarkers in a model of acute catecholamine cardiotoxicity. *Hum Exp Toxicol*, 2009, 28 (10), s. 631–640.
- Newby, L. K. – Rodriguez, I. – Finkle, J. – Becker, R. C. – Hicks, K. A., et al.: Troponin measurements during drug development—considerations for monitoring and management of potential cardiotoxicity: an educational collaboration among the Cardiac Safety Research Consortium, the Duke Clinical Research Institute, and the US Food and Drug Administration. *Am Heart J*, 2011, 162 (1), s. 64–73.
- O'Brien, P. J. – Dameron, G. W. – Beck, M. L., et al.: Cardiac troponin T is a sensitive, specific biomarker of cardiac injury in laboratory animals. *Lab Anim Sci*, 1997, 47 (5), s. 486–495.
- O'Brien, P. J.: Blood cardiac troponin in toxic myocardial injury: archetype of a translational safety biomarker. *Expert Rev Mol Diagn*, 2006, 6 (5), s. 685–702.
- O'Brien, P. J.: Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity. *Toxicology*, 2008, 245 (3), s. 206–218.
- Popelová, O. – Šterba, M. – Šimunek, T., et al.: Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo. *J Pharmacol Exp Ther*, 2008, 326 (1), s. 259–269.
- Popelová, O. – Šterba, M. – Hašková, P. – Šimunek, T. – Hroch, M. – Gunčova, I., et al.: Dexrazoxane-affected protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death. *Br J Cancer*, 2009, 101, s. 792–802.
- Reagan, W. J.: Troponin as a biomarker of cardiac toxicity: past, present, and future. *Toxicol Pathol*, 2010, 38 (7), s. 1134–1137.
- Šimunek, T. – Klímtová, I. – Kaplanová, J., et al.: Rabbit model for in vivo study of anthracycline induced heart failure and for the evaluation of protective agents. *Eur J Heart Fail*, 2004, 6, s. 377–387.
- Stevens, J. L. – Baker, T. K.: The future of drug safety testing: expanding the view and narrowing the focus. *Drug Discovery Today*, 2009, 14 (3–4), s. 162–167.
- Šterba, M. – Šimunek, T. – Popelová, O., et al.: Early detection of anthracycline cardiotoxicity in a rabbit model: left ventricle filling pattern versus troponin T determination. *Physiol Res*, 2007, 56 (5), s. 535–545.
- Šterba, M. – Popelova, O. – Lenco, J. – Fucikova, A., et al.: Proteomic insights into chronic anthracycline cardiotoxicity. *J Mol Cell Cardiol*, 2011, 50, s. 849–862.
- Tomomura, Y. – Mori, Y. – Torii, M. – Uehara, T.: Evaluation of the usefulness of biomarkers for cardiac and skeletal myotoxicity in rats. *Toxicology*, 2009, 266, s. 48–54.
- Wallace, K. B. – Hausner, E. – Herman, E.: Serum troponins as biomarkers of drug-induced cardiotoxicity. *Toxicol Pathol*, 2004, 32, s. 106–121.
- White, H. D.: Pathobiology of troponin elevations: do elevations occur with myocardial ischemia as well as necrosis? *J Am Coll Cardiol*, 2011, 57, s. 2406–2408.
- Wilkinson, J. M. – Grand, R. J. A.: Comparison of amino acid sequence of troponin I from different striated muscles. *Nature*, 1978, 271, s. 31–35.
- York, M. – Scudamore, C. – Brady, S., et al.: Characterization of troponin responses in isoproterenol-induced cardiac injury in the Hanover Wistar rat. *Toxicol Pathol*, 2007, 35, s. 606–617.
- Zhang, J. – Knapton, A. – Lipshultz, S. E. – Weaver, J. L. – Herman, E. H.: Isoproterenol-induced cardiotoxicity in Sprague-Dawley rats: correlation of reversible and irreversible myocardial injury with release of cardiac troponin T and roles of iNOS in myocardial injury. *Toxicol Pathol*, 2008, 36, s. 277–278.

## Glukokortikoidy šetřící léčba u systémového lupus erythematoses – zaměřeno na belimumab

MUDr. Hana Ciferská, Ph.D. Revmatologický ústav a Revmatologická klinika 1. LF UK a VFN, Praha  
MUDr. Jan Vachek Klinika nefrologie VFN a 1. LF UK, Praha

- Domic, R. T. – Ramsey-Goldman, R. – Manzi, S.: Epidemiology and classification of systemic lupus erythematosus. In: Hochberg, M. C. – Silman, A. J. – Smolen, J. S. – Weinblatt, M. E. – Weisman, M. H., editors: *Rheumatology*. 4. vydání, Philadelphia (PA), Mosby-Elsevier, 2008, s. 1211–1216.
- Hochberg, M. C., et al.: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum*, 1997, 40, s. 1725.
- Hochberg, M. C. – Silman, A. J. – Smolen, J. S. – Weinblatt, M. E. – Weisman, M. H., editors: *Rheumatology*. 4. vydání, Philadelphia (PA), Mosby-Elsevier, 2008, s. 1211–1216.
- Boneparth, A. – Davidson, A.: B-cell activating factor targeted therapy and lupus. *Arthritis Res Ther*. 2012, 14, dopl. 4, S2.
- Stohl, J.: BlySfúlness does not equal blissfulness in systemic lupus erythematosus: a therapeutic role for BlyS antagonists. *Curr Dir Autoimmun*, 2005, 8, s. 289–304.
- Tremblé, J. F. – Hao, Y. – Stadanick, J. E., et al.: The BlyS family: toward a molecular understanding of B cell homeostasis. *Cell Biochem Biophys*, 2009, 53, s. 1–16.
- Furie, R. – Petri, M. – Zamani, O. – Cervera, R., et al.: BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. *Arthritis Rheum*, 2011,

- 63, s. 3918–3930.
- 8 van Vollenhoven, R. F. – Mosca, M. – Bertsias, G., et al.: Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. *Ann Rheum Dis*, 2014, 73, s. 958–967.
  - 9 Horák, P. – Tezová, D. – Závada, Z., et al.: Doporučení ČRS pro léčbu nemocných se SLE. *Čes Revmatol*, 2013, 21, 3, s. 110–122.
  - 10 Gladman, D. D. – Urowitz, M. D. – Rahman, P. – Ibañez, D. – Tam, L. S.: Actual of organ damage over time in patients with systemic lupus erythematosus. *J Rheumatol*, 2003, 30, s. 1955–1959.
  - 11 Hamer, M. – Hernán, M. A. – Zhang, Y. – Cotter, D. – Petri, M.: Prednisone, lupus activity, and permanent organ damage. *J Rheumatol*, 2009, 36, s. 560–564.
  - 12 Lu, N. Z. – Cidlowski, J. A.: The origin and functions of multiple human glucocorticoid receptor isoforms. *Ann N Y Acad Sci*, 2004, 1024, s. 102–123.
  - 13 Stahn, C. – Buttgerit, F.: Genomic and nongenomic effects of glucocorticoids. *Nat Clin Pract Rheumatol*, 2008, 4, s. 525–533.
  - 14 Rhen, T. – Cidlowski, J. A.: Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. *N Engl J Med*, 2005, 353, s. 1711–1723.
  - 15 Gatto, M. – Kiss, E. – Naparstek, Y. – Doria, A.: In-/off-label use of biologic therapy in systemic lupus erythematosus. *BMC Med*, 2014, 17, 12, s. 30.
  - 16 Stohl, W.: Future prospects in biologic therapy for systemic lupus erythematosus. *Nat Rev Rheumatol*, 2013, 9, s. 705–720.
  - 17 Mosca, M. – Tani, C. – Aringer, M. – Bombardieri, S., et al.: European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. *Ann Rheum Dis*, 2010, 69, s. 1269–1274.
  - 18 Baker, K. P. – Edwards, B. M. – Main, S. H., et al.: Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. *Arthritis Rheum*, 2003, 48, s. 3253–3265.
  - 19 Human Genome Science BENLYSTA (belimumab), dostupné z: [www.hgsi.com/belimumab.html](http://www.hgsi.com/belimumab.html), vyhledáno 3. 12. 2014.
  - 20 van Vollenhoven, R. F. – Gallacher, A. – Navarra, S., et al.: Belimumab, a BlyS-Specific Inhibitor, Reduced Corticosteroid Use in Patients with Active SLE: Results from the Phase 3 BLISS-52 and -76 Studies (abstrakt). *Arthritis Rheum*, 2010, 62, dopl. 10, s. 451.
  - 21 Petri, M. – Levy, R. A. – Merrill, J. T., et al.: Belimumab, a BlyS-specific inhibitor, reduced disease activity, flares, and prednisone use in patients with seropositive SLE: combined efficacy results from the phase 3 BLISS-52 and -76 studies. *Arthritis Rheum*, 2010, 62, dopl. 10, s. 190.
  - 22 Cervera, R. – Furie, R. – Levy, R., et al.: Relationship of belimumab treatment response with corticoid use and severe flares in patients with SLE: BLISS-52 and BLISS-76. *Ann Rheum Dis*, 2011, 70, dopl. 3, s. 321.
  - 23 Navarra, S. V. – Guzmán, R. M. – Gallacher, A. E., et al.: BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. *Lancet*, 2011, 26, 377, s. 721–731.
  - 24 Furie, R. – Petri, M. – Zamani, O. – Cervera, R., et al.: BLISS-76 Study Group: A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. *Arthritis Rheum*, 2011, 63, s. 3918–3930.
  - 25 Navarra, S. – Ilianova, E. – Bae, S. C., et al.: Belimumab, a BlyS-specific inhibitor, reduced disease activity, flares, and steroid use in patients with seropositive systemic lupus erythematosus (SLE): BLISS-52 study. *Ann Rheum Dis*, 2010, 69, dopl. 3, s. 556.
  - 26 Collins, C. E. – Oglesby, M. – McGuire, A., et al.: 12-Month Outcomes Associated With Belimumab in Patients With Systemic Lupus Erythematosus In Clinical Practice Settings: The Observe Study (OP0048). *Ann Rheum Dis*, 2014, 73, dopl. 2.
  - 27 Ginzler, E. M. – Wallace, D. J. – Merrill, J. T., et al.: LBSL02/99 Study Group: Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. *J Rheumatol*, 2014, 41, s. 300–309.

## Mirabegron: nové možnosti terapie hyperaktivního močového měchýře

MUDr. Roman Staněk Urologické oddělení Slezské nemocnice Opava

- 1 Sein, A. J.: Pharmacologic options for the overactive bladder. *Urology Review*, 1998, 51 (2A dopl.), s. 43–47.
- 2 Abrams, P. – Freeman, R. – Anderström, C. – Mattiasson, A.: Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. *Br J Urol*, 1998, 81, s. 801–810.
- 3 Abrams, P. – Cardozo, L. – Fall, M. – Griffiths, D. – Rosier, P. – Ulmsten, U. – van Kerrebroeck, P. – Victor, A. – Wein, A.: The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. *Neurourol Urodyn*, 2002, 21, s. 167–178.
- 4 Irwin, D. E. – Milsom, I. – Hunskaar, S. – Reilly, K. – Kopp, Z. – Herschorn, S. – Coyne, K. – Kelleher, C. – Hampel, C. – Artibani, W. – Abrams, P.: Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. *Eur Urol*, 2006, 50, s. 1306–1314.
- 5 Milsom, I. – Abrams, P. – Cardozo, L. – Roberts, R. G. – Thüroff, J. – Wein, A. J.: How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. *BJU Int*, 2001, 87, s. 760–766.
- 6 Stewart, W. F. – Van Rooyen, J. B. – Cundiff, G. W. – Abrams, P. – Herzog, A. R. – Corey, R. – Hunt, T. L. – Wein, A. J.: Prevalence and burden of overactive bladder in the United States. *World J Urol*, 2003, 20, s. 327–336, Epub 15. 11. 2002.
- 7 Krhut, J. – Zachoval, R. – Martan, A. – Némec, D. – Havránek, O. – Sýkora, R. – Švábim, K. – Hanuš, T.: Prevalence symptomů hyperaktivního měchýře u pacientů urologických ambulancí. *Ces Urol*, 2011, 15, s. 181–188.
- 8 Reproductive and Urologic Drug Advisory Committee, s. 4. 2012.
- 9 Dale, P. R. – Cernecka, H. – Schmidt, M. – Bowling, M. R. – Charlton, S. J. – Pieper, M. P. – Michel, M. C.: The pharmacological rationale for combining muscarinic receptor antagonist and  $\beta$  adrenoceptor agonist in the treatment of airway and bladder disease. *Current Opinion in Pharmacology*, 2014, 16, s. 31–42.
- 10 Takeda, M. – Obara, K. – Mizusawa, T. – Tomita, Y. – Arai, K. – Tsutsui, T., et al.: Evidence for  $\beta$ 3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. *J Pharmacol Exp Ther*, 288, 1999, s. 1367–1373.
- 11 Takeda, H. – Yamazaki, Y. – Akahane, M. – Igawa, Y. – Ajisawa, Y. – Nishizawa, O.: Role of the  $\beta$ (3)-adrenoceptor in urine storage in the rat: comparison between the selective  $\beta$ (3)-adrenoceptor agonist, CL316, 243, and various smooth muscle relaxants. *J Pharmacol Exp Ther*, 2000, 293, s. 939–945.
- 12 Nomiya, M. – Yamaguchi, O.: A quantitative analysis of mRNA expression of  $\alpha$ 1 and  $\beta$ -adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. *J Urol*, 2003, 170, s. 649–653.
- 13 Andersson, K. – Chapple, C. – Cardozo, L. – Cruz, F. – Hashim, H. – Michel, M. C., et al.: Pharmacological treatment of urinary incontinence. In: Abrams, P. – Cardozo, L. – Khoury, S. – Wein, A. (eds): *Incontinence*, 4th International Consultation on Incontinence. Plymouth, 2009. UK, Plymbridge Distributors, s. 631–699.
- 14 Attachment 1: Product information for AusPAR Betmiga mirabegron. Astellas Pharma Australia Pty Ltd PM-2012-01928-3-3 Date of Finalisation 9. 1. 2014. This Product Information was approved at the time this AusPAR was published.
- 15 Krauwinkel, W. – van Gelderen, E. – Groen, M. – Schaddelee, M. – de Koning, P.: An openlabel crossover study to evaluate the effect of multiple doses of mirabegron on the pharmacokinetics of the CYP2D6 substrate desipramine in healthy subjects. *Clin Pharmacol Ther*, 2010, 87 (dopl. 1), abstrakt PI-43.
- 16 MYRBETRIO™ (mirabegron) extended-release tablets Prescribing Information, Astellas Pharmaceuticals, 2012.
- 17 Yamaguchi, O.:  $\beta$ 3-adrenoceptors in human detrusor muscle. *Urology*, 2002, 59 (dopl. 5A), s. 25–29.
- 18 Mirabegron (Myrbetriq) National Drug Monograph 21. Květen 2013, VA Pharmacy Benefits Management Services, Medical Advisory Panel and VSN Pharmacist Executives.
- 19 Takusagawa, S. – van Lier, J. – Suzuki, K. – Nagata, M. – Meijer, J. – Krauwinkel, W., et al.: Absorption, metabolism and excretion of [ $^{14}$ C] mirabegron (YM178), a potent and selective  $\beta$ 3-adrenoceptor agonist, after oral administration to healthy male volunteers. *Drug Metab Dispos*, 2012, 40, s. 815–824.
- 20 Chapple, Ch. R. – Dvorak, V. – Radziszewski, P. – van Kerrebroeck, P. – Wyndaele, J. J., et al., on behalf of the Dragon Investigator Group: A phase II dose-ranging study of mirabegron in patients with overactive bladder. *Int Urogynecol J*, 2013, 24, s. 1447–1458.
- 21 Chapple, C. R. – Wyndaele, J. J. – van Kerrebroeck, P., et al.: Dose-ranging study of once-daily Mirabegron (YM178), a novel selective  $\beta$ 3-adrenoceptor agonist, in patients with overactive bladder (OAB). Poster prezentován na 25th Annual European Association of Urology Meeting, 16.–20. dubna 2010, Barcelona, Španělsko. Poster 774.
- 22 Khullar, V. – Cambrono, J. – Angulo, J., et al.: Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder (OAB): post hoc analysis of a prospective, randomised, active- and placebo-controlled European–Australian Phase III trial. Poster prezentován na 28th Annual European Association of Urology Meeting, 24.–28. února 2012, Paříž, Francie. Poster 684.
- 23 Khullar, V. – Amarengo, G. – Angulo, J. C., et al.: Efficacy and tolerability of mirabegron, a  $\beta$ 3-adrenoceptor agonist, in patients with overactive bladder: results from a randomized European–Australian Phase 3 Trial. *Eur Urol*, 2013, 63, s. 283–295, doi: 10.1016/j.euro.2012.10.016, Epub 6. 11. 2012.
- 24 Chapple, C. R. – Kaplan, S. – Mitcheson, H. D., et al.: Randomized, double-blind, active-controlled phase III study to assess 12-month safety and efficacy of mirabegron, a  $\beta$ 3-adrenoceptor agonist, in overactive bladder (OAB). *Eur Urol*, 2013, 63, s. 296–305, doi: 10.1016/j.euro.2012.10.048, Epub 6. 11. 2012.
- 25 Kato, K. – Furuhashi, K. – Suzuki, K. – Murase, T. – Sato, E. – Gotoh, M.: Overactive bladder and glaucoma: a survey at outpatient clinics in Japan. *Int J Urol*, 2007, 14, s. 595–597.
- 26 Martin, N. E. – Lewis, R. A. – Vogel, R., et al.: Randomised, double-blind, placebo-controlled study to assess the ocular safety of mirabegron in normotensive IOP research subjects. Poster prezentován na 28th Annual European Association of Urology Meeting, 24.–28. února 2012, Paříž, Francie. Poster 686.
- 27 Yeaw, J., et al.: *J Manag Care Pharm*. 2009, 15, s. 728–740.
- 28 Ogihara, K. – Kaguyama, H. – Sakamoto, H. – Aonuma, K. – Matsuda, K. – Nakahira, Y. – Yanai, H. – Asakura, H.: Persistence with mirabegron in patients with overactive bladder: a comparative study of mirabegron and antimuscarinic: poster 576, 2014.
- 29 Maman, K. – Aballea, S. – Nazir, J. – Desroziers K. – Neine, M. E. – Siddiqui, E. – Odeyemi I. – Hakimi, Z.: Comparative efficacy and safety of medical treatments for the management of overactive bladder: A systematic literature review and mixed treatment comparison. *European Urology*, 2014, 65, s. 755–765.

## Metoprolol

prof. MUDr. Jan Bultas, CSc. Farmakologický ústav 3. LF UK Praha

- 1 Abrahamsson, T. – Ek, B. – Nerme, V.: The  $\beta$ 1- and  $\beta$ 2-adrenoceptor affinity of atenolol and metoprolol. A receptor-binding study performed with different radioligands in tissues from the rat, the guinea pig and man. *Biochem Pharmacol*, 1988, 37, s. 203–208.
- 2 Self, T. H. – Wallace, J. L. – Soberman, J. E.: Cardioselective  $\beta$ -blocker treatment of hypertension in patients with asthma: when do benefits outweigh risks? *J Asthma*, 2012, 49, s. 947–951.
- 3 Batty, J. A. – Hall, A. S. – White, H. L. – Wikstrand, J., et al.: An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy. *Clin Pharmacol Ther*, 2014, 95, s. 321–330.
- 4 Law, M. R. – Morfia, J. K. – Wald, N. J.: Use of blood pressure lowering

- drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. *BMJ*, 2009, 338, s. b1665.
- 5 Wikstrand, J. – Arnold, I. – Tomilehto, J., et al.: Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study. *Hypertension*, 1991, 17, s. 579–588.
  - 6 Heffernan, K. S. – Suryadevara R. – Patvardhan E. A., et al.: Effect of atenolol vs metoprolol succinate on vascular function in patients with hypertension. *Clin Cardiol*, 2011, 34, s. 39–44.
  - 7 Wikstrand, J. – Arnold, I. – Olsson, G., et al.: Primary prevention with metoprolol in patients with hypertension. *JAMA*, 1988, 259, s. 1976–1982.
  - 8 Galeeva, Z. M. – Galiavich, A. S.: Efficacy and tolerability of metoprolol retard in the treatment of patients with arterial hypertension and ischemic heart disease combined with type 2 diabetes mellitus. *Kardiologia*, 2009, 49, s. 25–27.
  - 9 Espinola-Klein, C. – Weisser, G. – Jagodzinski, A., et al.:  $\beta$ -Blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial. *Hypertension*, 2011, 58, s. 148–154.
  - 10 Batsisky, D. L. – Sorof, J. M. – Sugg, J., et al.: Efficacy and safety of extended release metoprolol succinate in hypertensive children 6 to 16 years of age: a clinical trial experience. *J Pediatr*, 2007, 150, s. 134–139.
  - 11 Petersen, K. M. – Jimenez-Solem, E. – Andersen, J. T., et al.:  $\beta$ -Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study. *BMJ*, 2012, 2, s. e001185, doi: 10.1136.
  - 12 Tomei, G. – Mosti, G. – Veltri, M., et al.: Effect of metoprolol on the exercise tolerance in patients with stable angina pectoris. *G Ital Cardiol*, 1978, 8, s. 1286–1292.
  - 13 Uusitalo, A. – Keyriläinen, O. – Johnsson, G. A.: dose-response study on metoprolol in angina pectoris. *Ann Clin Res*, 1981, 13, s. 54–57.
  - 14 Hjelmah, P. – Ericsson, S. V. – Held, C., et al.: Favourable long term prognosis in stable angina pectoris: an extended follow up of the angina prognosis study in Stockholm (APSYS). *Heart*, 2006, 92, s. 177–182.
  - 15 Hjalmarson, A. – Elmfeldt, D. – Herlitz, J., et al.: Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. *Lancet*, 1981, 2, s. 823–827.
  - 16 Salathia, K. S. – Barber, J. M. – McIlmoyle, E. L., et al.: Very early intervention with metoprolol in suspected acute myocardial infarction. *Eur Heart J*, 1985, 6, s. 190–198.
  - 17 Manger, C. V. – van Capelle, F. J. L. – Lie, K. I., et al.: Effect of treatment with 2x 100 mg metoprolol on mortality in a single-center study with low placebo mortality rate after infarction. *Circulation*, 1983, 68, s. 181.
  - 18 Olsson, G. – Rehnqvist, N. – Sjögren, A., et al.: Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity. *J Am Coll Cardiol*, 1985, 5, s. 1428–1437.
  - 19 Hjalmarson, A. – Elmfeldt, D. – Herlitz, J., et al.: Effect on mortality of metoprolol in acute myocardial infarction. A randomized double-blind trial. *Munch Med Wochenschr*, 1982, 124, s. 32–45.
  - 20 MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial In Congestive Heart Failure (MERIT-HF). *Lancet*, 1999, 353, s. 2001–2007.
  - 21 Hjalmarson, A. – Goldstein, S. – Fagerberg, B., et al.: Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). *JAMA*, 2000, 283, s. 1295–1302.
  - 22 Poole-Wilson, P. A. – Swedberg, K. – Cleland, J. G., et al.: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. *Lancet*, 2003, 362, s. 7–13.
  - 23 Remme, W. J. – Cleland, J. G. – Erhardt, L., et al.: Effect of carvedilol and metoprolol on the mode of death in patients with heart failure. *Eur J Heart Fail*, 2007, 9, s. 1128–1135.
  - 24 Wikstrand, J. – Wedel, H. – Castagno, D. – McMurray, J. J.: The large-scale placebo-controlled  $\beta$ -blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF. *J Intern Med*, 2014, 275, s. 134–143.
  - 25 Amsterdam, E. A. – Kulcyski, J. – Ridgeway, M. G., et al.: Efficacy of cardioselective  $\beta$ -adrenergic blockade with intravenously administered metoprolol in the treatment of supraventricular tachyarrhythmias. *J Clin Pharmacol*, 1991, 31, s. 714–718.
  - 26 Kangasniemi, P. – Andersen, A. R. – Anderson, P. G., et al.: Classic migraine: effective prophylaxis with metoprolol. *Cephalalgia*, 1987, 7, s. 231–238.
  - 27 Brixius, K. – Middeke, M. – Lichtenthal, A., et al.: Nitric oxide, erectile dysfunction and  $\beta$ -blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. *Clin Exp Pharmacol Physiol*, 2007, 34, s. 327–331.
  - 28 Molden, E. – Spigset, O.: Interactions between metoprolol and antidepressants. *Tidsskr Nor Laegeforen*, 2011, 131, s. 1777–1779.
  - 29 Fukumoto, K. – Kobayashi, T. – Tachibana, K., et al.: Effect of amiodarone on the serum concentration/dose ratio of metoprolol in patients with cardiac arrhythmia. *Drug Metab Pharmacokin*, 2006, 21, s. 501–505.
  - 30 Blake, C. M. – Kharasch, E. D. – Schwab, M. – Nagele, P. A.: Eta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics. *Clin Pharmacol Ther*, 2013, 94, s. 394–399.
  - 31 Pasternak, B. – Swanström, H. – Melbye, M., et al.: Association of treatment with carvedilol vs metoprolol succinate and mortality in patients with heart failure. *JAMA Intern Med*, 2014, 174, doi: 10.1001/jamainternmed.2014.3258.

## AMESOS – fixní kombinace lisinoprilu a amlodipinu v léčbě hypertenze

MUDr. Jiří Slíva, MD., Ph.D. Ústavy farmakologie 2. a 3. LF UK Praha

- 1 Murdoch, D. – Heel, R. C.: Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. *Drugs*, 1991, 41, s. 478–505.
- 2 Goa, K. L. – Haria, M. – Wilde, M. I.: Lisinopril. A review of its pharmacology and use in the management of the complications of diabetes mellitus. *Drugs*, 1997, 53, s. 1081–1105.
- 3 Bramley, T. J. – Gerbino, P. P. – Nightengale, B. S. – Frech-Tamas, F.: Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. *J Manag Care Pharm*, 2006, 12, s. 239–245.
- 4 Corrao, G. – Nicotra, F. – Parodi, A., et al.: Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. *Hypertension*, 2011, 58, s. 566–572.
- 5 Dickson, M. – Plauschinat, C. A.: Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benzepiril versus component-based free-combination therapy. *Am J Cardiovasc Drugs*, 2008, 8, s. 45–50.
- 6 Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. *Lancet*, 1997, 349, s. 1787–1792.
- 7 Abraham, G. – Boda, K. – Legrady, P. – Letoha, A.: The effect of Lisopres® treatment on ambulatory blood pressure and urinary microalbumin excretion in patients with hypertension and diabetes. *Hypertension and nephrology*, 2003, 7, s. 13–20.
- 8 Pilote, L. – Abrahamowicz, M. – Eisenberg, M. – Humphries, K. – Behloul, H. – Tu, J. V.: Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. *CMAJ*, 2008, 178, s. 1303–1311.
- 9 Pall, D. – Katona, E. – Juhasz, M. – Paragh, G.: Prevention of target organ damage with modern antihypertensive agents. *Orv Hetil*, 2006, 147, s. 1505–1511.
- 10 Farsang, C. – Abraham, G. – Kovacs, P. – Karanyi, Z. – Ofner, P.: The effectivity and safety of Amlodipin-Lisinopril Fix-combination in patients with ESsential hypertension (ALFESS study). *Hypertension and nephrology*, 2009, 13, s. 81–88.
- 11 Krupička, J. – Souček, M. – Widimský, J. – Franc, P.: Projekt Györgyi – neintervenci sledování účinnosti a tolerance léčby hypertenze přípravkem Amesos prostřednictvím 24hodinové kontroly krevního tlaku. *ACTA MEDICINAE: Vnitřní lékařství*, 2014, 9, s. 50–55.

## Farmakologická léčba obezity a diabetu

prof. MUDr. Martin Haluzík, DrSc. III. interní klinika 1. LF UK a VFN, Praha

### Kompletní seznam je k dispozici u autora

- 1 O'Rahilly, S.: Science, medicine, and the future. Non-insulin dependent diabetes mellitus: the gathering storm. *BMJ*, 1997, 314, s. 955–959.
- 2 Reaven, G.: Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. *Circulation*, 2002, 106, s. 286–288.
- 3 Reaven, G. – Abbasi, F. – McLaughlin, T.: Obesity, insulin resistance, and cardiovascular disease. *Recent progress in hormone research*, 2004, 59, s. 207–223.
- 4 Despres, J. P.: Cardiovascular disease under the influence of excess visceral fat. *Crit Pathw Cardiol*, 2007, 6, s. 51–59.
- 5 Dolinkova, M. – Dostalova, I. – Lacinova, Z., et al.: The endocrine profile of subcutaneous and visceral adipose tissue of obese patients. *Molecular and cellular endocrinology*, 2008, 291, s. 63–70.
- 6 Bluher, M.: Adipose tissue dysfunction in obesity. *Exp Clin Endocrinol Diabetes*, 2009, 117, s. 241–250.
- 7 Sjöstrom, L. – Narbro, K. – Sjöstrom, C. D., et al.: Effects of bariatric surgery on mortality in Swedish obese subjects. *The New England Journal of Medicine*, 2007, 357, s. 741–752.
- 8 Borghouts, L. B. – Keizer, H. A.: Exercise and insulin sensitivity: a review. *International Journal of Sports Medicine*, 2000, 21, s. 1–12.
- 9 Delahanty, L. M. – Halford, B. N.: The role of diet behaviors in achieving improved glycemic control in intensively treated patients in the Diabetes Control and Complications Trial. *Diabetes Care*, 1993, 16, s. 1453–1458.
- 10 Dixon, J. B. – le Roux, C. W. – Rubino, F. – Zimmet, P.: Bariatric surgery for type 2 diabetes. *Lancet*, 2012, 379, s. 2300–2311.
- 11 Fried Mea: *Bariatrická a metabolická chirurgie*. Praha, Mladá fronta, 2011.
- 12 Maetzel, A. – Ruof, J. – Covington, M. – Wolf, A.: Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus. *Pharmacoeconomics*, 2003, 21, s. 501–512.
- 13 Bray, G. A. – Ryan, D. H.: Update on obesity pharmacotherapy. *Annals of the New York Academy of Sciences*, 2014, 1311, s. 1–13.
- 14 Svačina, Š. – Sucharda, P. – Stránská, Z. – Matoulek, M.: Perspective of obesity pharmacotherapy. *Casopis lékařu českých*, 2014, 153, s. 127–130.
- 15 Cummings, D. E.: Endocrine mechanisms mediating remission of diabetes after gastric bypass surgery. *International Journal of Obesity* (2005) 2009, 33, dopl. 1, s. S33–S40.
- 16 Wohl, P. – Krušinová, E. – Kratochvílová, S., et al.: Inzulínová rezistence u diabetiků – metabolická inflexibilita. *DMEV*, 2005, 8, s. 174–178.
- 17 Haluzík, M., et al.: *Praktická léčba diabetu*. Praha, Mladá fronta, 2009.
- 18 Blaschke, F. – Spanheimer, R. – Khan, M. – Law, R. E.: Vascular effects of TZDs: New implications. *Vascular Pharmacology*, 2006.
- 19 Ampudia-Blasco, F. J. – Rossetti, P. – Ascaso, J. F.: Basal plus Basal-bolus approach in type 2 diabetes. *Diabetes technology & therapeutics*, 2011, 13, dopl. 1, s. S75–S83.
- 20 Haluzík, M. – Svačina, Š.: *Inzulínová léčba diabetu*. Praha, Mladá fronta, 2010.
- 21 Deacon, C. F. – Mannucci, E. – Ahren, B.: Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes – a review and meta analysis. *Diabetes, Obesity & Metabolism*, 2012, 14, s. 762–767.
- 22 Abdul-Ghani, M. A. – DeFronzo, R. A.: Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. *Endocrine practice*, 2008, 14, s. 782–790.
- 23 Anderson, S. L. – Marrs, J. C.: Dapagliflozin for the treatment of type 2 diabetes. *The Annals of Pharmacotherapy*, 2012, 46, s. 590–598.

# Praktické využití fixní kombinace perindopril/indapamid u nemocného s metabolickým syndromem

doc. MUDr. Jitka Seidlerová, Ph.D. Lékařská fakulta v Plzni, Univerzita Karlova v Praze,  
Biomedicínské centrum, Lékařská fakulta v Plzni, Univerzita Karlova v Praze, Plzeň

- 1 **Filipovský, J., et al.**: Diagnostické a léčebné postupy u arteriální hypertenze – verze 2012. Doporučení České společnosti pro hypertenzi. *Vnitř Lék*, 2012, 58, s. 785–801.
- 2 **Cífková, R., et al.**: Prevalence základních kardiovaskulárních rizikových faktorů v české populaci v letech 2006–2009. Studie Czech post-MO-NICA. *Cor et Vasa*, 2011, 53, s. 220–229.
- 3 **Alberti, K. G., et al.**: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation*, 2009, 120, s. 1640–1645.
- 4 **van Vark, L. C., et al.**: Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. *Eur Heart J*, 2012, 33, s. 2088–2097.
- 5 **Patel, A., et al.**: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. *Lancet*, 2007, 370, s. 829–840.
- 6 **Beckett, N. S., et al.**: Treatment of hypertension in patients 80 years of age or older. *N Engl J Med*, 2008, 358, s. 1887–1898.
- 7 **Dahlof, B., et al.**: Prevention of cardiovascular events with an anti-hypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. *Lancet*, 2005, 366, s. 895–906.
- 8 **Zoungas, S., et al.**: Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. *N Engl J Med*, 2014, 371, s. 1392–1406.
- 9 **PROGRESS Collaborative Group**. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. *Lancet*, 2001, 358, s. 1033–1041.
- 10 **Dahlof, B., et al.**: Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. *J Hypertens*, 2005, 23, s. 2063–2070.
- 11 **Mogensen, C. E., et al.**: Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. *Hypertension*, 2003, 41, s. 1063–1071.
- 12 **Mourad, J. J., et al.**: Improvement of impaired coronary vasodilator reserve in hypertensive patients by low-dose ACE inhibitor/diuretic therapy: a pilot PET study. *J Renin Angiotensin Aldosterone Syst*, 2003, 4, s. 94–95.
- 13 **Asmar, R. G., et al.**: Amelioration of arterial properties with a perindopril-indapamide very-low-dose combination. *J Hypertens Suppl*, 2001, 19, s. 15–20.
- 14 **Bangalore, S., Kamalakkannan, G., Parkar, S., Nessedli, F. H.**: Fixed-dose combinations improve medication compliance: a meta-analysis. *Am J Med*, 2007, 120, s. 713–719.
- 15 **Kuo, S. W., et al.**: Effect of indapamide SR in the treatment of hypertensive patients with type 2 diabetes. *Am J Hypertens*, 2003, 16, s. 623–628.
- 16 **Ames, R. P.**: A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides. *Am J Cardiol*, 1996, 77, s. 12b–16b.
- 17 **Mancia, G., Parodi, A., Merlino, L., Corrao, G.**: Heterogeneity in antihypertensive treatment discontinuation between drugs belonging to the same class. *J Hypertens*, 2011, 29, s. 1012–1018.
- 18 **Agarwal, R.**: Hypertension, hypokalemia, and thiazide-induced diabetes: a 3-way connection. *Hypertension*, 2008, 52, s. 1012–1013.

## Personalizovaná léčba deprese

prof. MUDr. Jiří Raboch, DrSc. Psychiatrická klinika 1. LF UK a VFN

- 1 **Barber, J. P., Muenz, L. R.**: The role of avoidance and obsessiveness in matching patients to cognitive and interpersonal psychotherapy: Empirical findings from the Treatment for Depression Collaborative Research Program. *J Consult Clin Psychol*, 1996, 64, s. 951–958.
- 2 **Bauer, M., et al.**: World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders. *The World J Biol Psychiatry*, 2013, 14, s. 334–385.
- 3 **DeRubeis, R. J., et al.**: The Personalized Advantage Index: translating research on prediction into individualized treatment recommendations. A demonstrative. *PLoS One*, 9, 2014, 1, e83875.
- 4 **GENDEP, MARS, STAR\*D**. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of free Genome-Wide pharmacogenetic studies. *Am J Psychiatry*, 2013, 170, 2, s. 207–217.
- 5 **Hunter, A. M., et al.**: The Antidepressant Treatment Response (ATR) Index and treatment outcomes in a placebo-controlled trial of fluoxetine. *J Clin Neurophysiol*, 2011, 28, 5, s. 478–482.
- 6 **Insel, T. R.**: The NIMH Research Domain Criteria (RDoC) Project: precision medicine for psychiatry. *Am J Psychiatry*, 2014, 171, 4, s. 395–397.
- 7 **Landro, N. I.**: Towards personalized treatment of depression: a candidate gene approach. *Scand J Psychol*, 2014, 55, 3, s. 219–224.
- 8 **Leuchter, A. F., et al.**: Biomarkers to predict antidepressant response. *Curr Psychiatry Rep*, 2010, 12, s. 553–562.
- 9 **Ozomaro, U., et al.**: Personalized medicine in psychiatry: problems and promises. *BMC Medicine*, 2013, 11, 132, s. 1–35.
- 10 **Papakostas, G. I., et al.**: Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotypes: results from a randomized clinical trial. *J Clin Psychiatry*, 2014, 75, 8, s. 855–863.
- 11 **Raboch, J., et al.**: *Psychiatrie: Doporučené postupy psychiatrické péče IV*. Psychiatrická společnost ČLS JEP, Praha 2014, s. 208.
- 12 **Simon, G. E., Perlis, R. H.**: Personalized medicine for depression: can we match patients with treatments? *Am J Psychiatry*, 2010, 167, 12, s. 1445–1455.
- 13 **Uher, R., et al.**: An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. *Am J Psychiatry*, 2014, doi: 10.1176/appi.ajp.2014.14010094.
- 14 **Zajkowska, Z. E., et al.**: Towards a personalized treatment in depression: endocannabinoids, inflammation and stress response. *Pharmacogenomics*, 2014, 15, 5, s. 687–698.

## Individualizace farmakologické léčby v psychiatrii – zaostřeno na schizofrenii

prof. MUDr. Eva Češková, CSc. CEITEC – MU, Psychiatrická klinika FN Brno,

Katedra interních oborů LF Ostravské univerzity v Ostravě, Oddělení psychiatrické FN Ostrava

prof. MUDr. Ladislav Hosák, Ph.D. Psychiatrická klinika LF UK a FN Hradec Králové

- 1 **Wegener, G., Rujescu, D.**: The current development of CNS drug research. *Int J Neuropsychopharmacol*, 2013, 16, s. 1687–1693.
- 2 **Češková, E., Příkrýl, R., Peč, O.**: Schizofrenie u dospělých. In: *Psychiatrie: Doporučené postupy psychiatrické péče IV*. Praha: Psychiatrická společnost ČLS JEP, 2014, s. 44–51.
- 3 **Hasan, A., Falkai, P., Wobrock, T., et al.**: World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. *World J Biol Psychiatry*, 2012, 13, s. 318–378.
- 4 **Hasan, A., Falkai, P., Wobrock, T., et al.**: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. *World J Biol Psychiatry*, 2013, 14, s. 2–44.
- 5 **Larsen, T. M., Munk-Olsen, T., Vestergaard, M.**: Life expectancy and cardiovascular mortality in persons with schizophrenia. *Curr Opin Psychiatry*, 2012, 25, s. 83–88.
- 6 **Correll, C. U.**: From receptor pharmacology to improved outcomes in individualising the selection, dosing and switching of antipsychotics. *Eur Psychiatry*, 2010, suppl. 2, s. 12–21.
- 7 **Mokhtari, M., Rajarethinam, R.**: Early intervention and the treatment of prodrome in schizophrenia: a review of recent developments. *J Psychiatr Pract*, 2013, 19, s. 375–385.
- 8 **Češková, E.**: *Schizofrenie a její léčba*. 3. vydání. Praha: Maxdorf-Jessenius, 2012, 270.
- 9 **Češková, E.**: Schizofrenie. *Postgraduální medicína*, 2013, 15, s. 90–98.
- 10 **Kishi, T., lwata, N.**: Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia. *Int J Neuropsychopharmacol*, 2014, 17, s. 343–354.
- 11 **Michalopoulou, P. G., Lewis, S. W., Wykes, T., Jaeger, J., Kapur, S.**: Treating impaired cognition in schizophrenia: the case for combining cognitive-enhancing drugs with cognitive remediation. *Eur Neuropsychopharmacol*, 2013, 23, s. 790–798.
- 12 **Arranz, M. J., Rivera, M., Munro, J. C.**: Pharmacogenetics of response to antipsychotics in patients with schizophrenia. *CNS Drugs*, 2011, 25, s. 933–969.
- 13 **Mas, S., Lierena, A., Saiz, J., Bernardo, M., Lafuente, A.**: Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study. *Pharmacogenomics*, 2012, 13, s. 1773–1782.
- 14 **Hiemke, C., Baumann, P., Bergmann, N., et al.**: AGNP consensus guideline for therapeutic drug monitoring in psychiatry: update 2011. *Pharmacopsychiatry*, 2011, 44, s. 195–235.

# Dlouhodobá účinnost glatiramer acetátu v podmínkách klinické praxe

MUDr. Jiří Slíva, MD., Ph.D. Ústavy farmakologie 2. a 3. LF UK Praha

- 1 Arnal-García, C. – Amigo-Jorrin, M. D. – López-Real, A. M. – Lema-Devesa, C. – Llopis, N. – Rosa, R. S. – XPERIENCIA-5 Study Group: Long-term effectiveness of glatiramer acetate in clinical practice conditions. *Journal of Clinical Neuroscience*. Publikováno před tiskem 22. 9. 2014, doi: 10.1016/j.jocn.2014.05.045.
- 2 Cadavid, D. – Wolansky, L. J. – Skurnick, J. – Lincoln, J. – Cheriyan, J. – Szczepanowski, K. – Kamin, S. S. – Pachner, A. R. – Halper, J. – Cook, S. D.: Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. *Neurology*, 2009, 72, s. 1976–1983.
- 3 Comi, G. – Filippi, M. – Wolinsky, J. S.: European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. *Annals of Neurology*, 2001, 49, s. 290–297.
- 4 Johnson, K. P. – Brooks, B. R. – Cohen, J. A. – Ford, C. C. – Goldstein, J. – Lisak, R. P. – Myers, L. W. – Panitch, H. S. – Rose, J. W. – Schiffer, R. B.: Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. *Neurology*, 1995, 45, s. 1268–1276.
- 5 Mikol, D. D. – Barkhof, F. – Chang, P. – Coyle, P. K. – Jeffery, D. R. – Schwid, S. R. – Stubinski, B. – Uitdehaag, B.: REGARD study group: Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REBif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicenter, randomised, parallel, open-label trial. *Lancet Neurology*, 2008, 7, s. 903–914.
- 6 O'Connor, P. – Filippi, M. – Arnason, B. – Comi, G. – Cook, S. – Goodin, D. – Hartung, H. P. – Jeffery, D. – Kappos, L. – Boate, F. – Filipov, V. – Groth, M. – Knappertz, V. – Kraus, C. – Sandbrink, R. – Pohl, C. – Bogumil, T.: 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. *Lancet Neurology*, 2009, 8, s. 889–897.
- 7 Qizilbash, N. – Mendez, I. – Sanchez-de la Rosa, R.: Benefit-risk analysis of glatiramer acetate for relapsing-remitting and clinically isolated syndrome multiple sclerosis. *Clinical Therapy*, 2012, 34, s. 159–176.
- 8 Ford, C. – Goodman, A. D. – Johnson, K. – Kachuck, N. – Lindsey, J. W. – Lisak, R. – Luzzio, C. – Myers, L. – Panitch, H. – Preisingerova, J. – Pruitt, A. – Rose, J. – Rus, H. – Dolinsky, J.: Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. *Multiple Sclerosis*, 2010, 16, s. 342–350.
- 9 Rovaris, M. – Comi, G. – Rocca, M. A. – Valsasina, P. – Ladkani, D. – Pieri, E. – Weiss, S. – Shifroni, G. – Dolinsky, J. S. – Filippi, M. – European/Canadian Glatiramer Acetate Study Group: Long-term follow-up of patients treated with glatiramer acetate: a multicenter, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial. *Multiple Sclerosis*, 2007, 13, s. 502–508.
- 10 Fernandez, O.: Clinical utility of glatiramer acetate in the management of relapse frequency in multiple sclerosis. *Journal of Central Nervous System Disease*, 2012, 4, s. 117–133.
- 11 Johnson, K. P. – Brooks, B. R. – Ford, C. C. – Goodman, A., et al.: Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. *Multiple Sclerosis*, 2000, 6, s. 255–266.
- 12 Ford, C. C. – Johnson, K. P. – Lisak, R. P. – Panitch, H. S. – Shifroni, G. – Dolinsky, J. S. – Copaxone Study Group: A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. *Multiple Sclerosis*, 2006, 12, s. 309–320.
- 13 Johnson, K. P. – Ford, C. C. – Lisak, R. P. – Dolinsky, J. S.: Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. *Acta Neurologica Scandinavica*, 2005, 111, s. 42–47.
- 14 Debouverie, M. – Moreau, T. – Lebrun, C. – Heinzel, O. – Brusin, F. – Mshid, J.: A longitudinal observational study of a cohort of patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate. *European Journal of Neurology*, 2007, 14, s. 1266–1274.
- 15 Sinic, C. J. – Seeldrayers, P. – Vande Gaer, L. – De Smet, E., et al.: Long-term follow up of glatiramer acetate compassionate use in Belgium. *Acta Neurologica Belgica*, 2005, 105, s. 81–85.
- 16 Miller, A. – Spada, V. – Beerkircher, D. – Kreitman, R. R.: Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis. *Multiple Sclerosis*, 2008, 14, s. 494–499.
- 17 Fernández-Fernández, Ó. – García-Trujillo, L. – Guerrero-Fernández, M., et al.: The effectiveness of glatiramer acetate in clinical practice: an observational study. *Review of Neurology*, 2012, 54, s. 1–9.
- 18 Haas, J. – Firzlaif, M.: Twenty-four-month comparison of immunomodulatory treatments—a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (COPAXONE). *European Journal of Neurology*, 2005, 12, s. 425–431.
- 19 Carrá, A. – Onaha, P. – Sinay, V. – Alvarez, F. – Luetic, G. – Bettinelli, R. – San Pedro, E. – Rodríguez, L.: A retrospective, observational study comparing the four available immunomodulatory treatments for relapsing-remitting multiple sclerosis. *European Journal of Neurology*, 2003, 10, s. 671–676.
- 20 Castelli-Haley, J. – Oleen-Burkey, M. A. – Lage, M. J. – Johnson, K.: Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts. *Journal of Medical Economics*, 2010, 13, s. 464–471.
- 21 Lublin, F. D. – Cofield, S. S. – Cutter, G. R. – Conwit, R. – Narayana, P. A., et al.: CombiRx Investigators: Randomized study combining interferon and glatiramer acetate in multiple sclerosis. *Annals of Neurology*, 2013, 73, s. 327–340.
- 22 Dolinsky, J. S. – Narayana, P. A. – Johnson, K. P.: United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center. *Multiple Sclerosis*, 2001, 7, s. 33–41.

## Nové trendy ve vakcinologii

MUDr. Veronika Horáková Ústav imunologie 2. LF a FN v Motole, Praha

- 1 Siegrist, C. A.: *Vaccines*. Elsevier Saunders, 2013, s. 14–32.
- 2 Plotkin, S. A.: *Vaccines: the Fourth Century*. *Clin Vaccine Immunol*, 2009, 16, s. 1709–1719.
- 3 Ahmad, H. – Chapnick, E. K.: Conjugated polysaccharide vaccines. *Infect Dis Clin N Am*, 1999, 13, s. 113–133.
- 4 Coffman, R. L. – Sher, A. – Seder, R. A.: Vaccine adjuvants: putting innate immunity to work. *Immunity*, 2010, 33, s. 492–503.
- 5 Donati, C. – Rappuoli, R.: Reverse vaccinology in the 21<sup>st</sup> century: improvements over the original design. *Ann NY Acad Sci*, 2013, 1285, s. 115–132.
- 6 Thors, V. S. – Marlow, R. D. – Finn, A.: Current developments and trends in childhood immunization. *Paediatr Child Health*, 2013, 23, s. 103–108.
- 7 De Gregorio, E. – Tritto, E. – Rappuoli, R.: Alum adjuvant: unravelling a century old mystery. *Eur J Immunol*, 2008, 38, s. 2068–2071.
- 8 Lambrecht, B. N. – Kool, M. – Willart, M. A., et al.: Mechanism of action of clinically approved adjuvants. *Curr Opin Immunol*, 2009, 21, s. 23–29.
- 9 Puledran, B. – Hed, R.: Immunological mechanism of vaccination. *Nat Immunol*, 2011, 12, s. 509–517.
- 10 Shoenfeld, Y. – Agmon Levin, N.: ASIA – Autoimmune/inflammatory syndrome induced by adjuvants. *J Autoimmun*, 2011, 36, s. 4–8.
- 11 Israeli, E. – Agmon Levin, N. – Blank, M. – Shoenfeld, Y.: Macrophagic myofasciitis a vaccine (alum) autoimmune related disease. *Clin Rev Allerg Immunol*, 2001, 41, s. 163–168.
- 12 Didierlaurent, A. M. – Morel, S. – Lochman, L., et al.: AS04, an aluminium salt and TLR 4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. *J Immunol*, 2009, 183, s. 6186–6197.
- 13 Belshe, R. B. – Edwards, K. M. – Vesikari, T. – Blafi, V., et al.: Live attenuated versus inactivated influenza vaccine in infants and young children. *N Engl J Med*, 2007, 356, s. 685–696.
- 14 Laurent, P., et al.: Evaluation of the clinical performance of new intradermal vaccine administration technique and associated delivery system. *Vaccine*, 2007, 25, s. 8833–8842.
- 15 Donnelly, J. – Medini, D. – Boccardi, G., et al.: Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. *Proc Natl Acad Sci USA*, 2010, 107, s. 19490–19495.
- 16 Křížová, P. – Musílek, M. – Vacková, Z., et al.: Invazivní meningokové onemocnění v České republice v roce 2011. *Zprávy centra epidemiologie a mikrobiologie*, 2012, 21, s. 106–111.
- 17 Markowitz, L. E. – Harii, S., et al.: Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. *J Infect Dis*, 2013, 208, s. 385–393.
- 18 Plotkin, S. A.: *Vaccines, Vaccination, and Vaccinology*. *J Infect Dis*, 2003, 187, s. 1349–1359.

## Avanafil – nová možnost volby v léčbě erektilní dysfunkce

MUDr. Lukáš Bittner, FEBU, FECSM Urologická klinika 3. LF UK a FNKV

- 1 Weiss, P. – Zvěřina, J.: *Sexuální chování v ČR*. 1993, 1998, 2003, 2008.
- 2 Porst, H.: Use of avanafil and successful intercourse within approximately 15 minutes of dosing in men with mild to severe erectile dysfunction. *European Urology Supplements*, 2014, 13, s. e600–e600a.
- 3 Goldstein, I. – McCullough, A. R. – Jones, L. A. – Hellstrom, W. J. – Bowden, C. H., et al.: A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. *J Sex Med*, 2012, 9, s. 1122–1133.
- 4 Wang, R. – Burnett, A. L. – Heller, W. H., et al.: Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. *J Sex Med*, 2012, 9, s. 2122–2129.
- 5 Katz, E. G. – Tan, R. B. – Rittenberg, D., et al.: Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and clinical utility. *Ther Clin Risk Manag*, 2014, 10, s. 701–711.
- 6 Cui, Y. S. – Li, N. – Zong, H. T. – Yan, H. L. – Zhang, Y.: Avanafil for male erectile dysfunction: a systematic review and meta-analysis. *Asian J Androl*, 2014, 16, s. 472–477.
- 7 Goldstein, I. – Jones, L. A. – Belkoff, L. H., et al.: Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus. *Mayo Clin Proc*, 2012, 87, s. 843–852.